XML 47 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2011

Stockholders' Equity

Summary Of Activity Under Stock Incentive Plans


		Number of Shares				Weighted Average Exercise Price				Weighted Average Remaining Contractual Term				Aggregate Intrinsic Value
Outstanding, January 1, 2011			5,891,400			$	22.60
Granted			3,617,599			$	29.55
Exercised			(890,371	)		$	22.85
Forfeited			(178,246	)		$	24.27
Expired			(4,261	)		$	26.35

Outstanding, June 30, 2011			8,436,121			$	25.54				7.44			$	120,920,079
Vested and expected to vest, June 30, 2011			7,654,921			$	25.24				7.36			$	111,988,971
Exercisable, June 30, 2011			2,267,239			$	23.57				6.01			$	36,947,697

Stock Option Assumption


		2011				2010
Average expected term (years)			5.0				5.3
Risk-free interest rate			2.1	%			2.6	%
Dividend yield			0.00				0.00
Expected volatility			32	%			34	%

Summary Of Restricted Stock Units


		Number of Shares				Aggregate Intrinsic Value
Outstanding, January 1, 2011			2,211,303
Granted			1,046,788
Forfeited			(111,867	)
Vested			(531,085	)

Outstanding, June 30, 2011			2,615,139			$	104,252,542
Vested and expected to vest, June 30, 2011			2,264,620			$	89,326,129

Summary Of Restricted Stock Awards


		Number of Shares				Weighted Average Fair Value Per Share				Aggregate Intrinsic Value
Outstanding, January 1, 2011			—			$	—
Granted			199,413			$	38.32
Forfeited			—			$	—
Vested			—			$	—			$	—

Non-vested, June 30, 2011			199,413			$	38.32

Changes In Stockholders' Equity


		Attributable to:
		Endo Pharmaceuticals Holdings Inc.				Noncontrolling interests				Total Stockholders' Equity
Stockholders' equity at January 1, 2011		$	1,741,591			$	61,738			$	1,803,329
Net income			110,370				25,477				135,847
Other comprehensive income			(382	)			—				(382	)
Compensation related to stock-based awards			18,772				—				18,772
Exercise of options			20,464				—				20,464
Common stock purchased			(34,701	)			—				(34,701	)
Distributions to noncontrolling interests			—				(25,813	)			(25,813	)
Buy-out of noncontrolling interests, net of contributions			—				(524	)			(524	)
Replacement equity issued in connection with the AMS acquisition			12,220				—				12,220
Other			3,822				—				3,822

Stockholders' equity at June 30, 2011		$	1,872,156			$	60,878			$	1,933,034

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References+ Details